Few investors think about where the bacon in their sandwich started out, but Genus (LSE:GNS) has built a FTSE 350 Business on that question. Its PIC division supplies breeding pigs to many of the world's largest pork producers, and its ABS division sells bull semen to dairy and beef farmers. Each generation of animals is selected for traits that make farmers more money, such as faster growth, better feed conversion, larger litters and hardier animals, and those gains are passed down the Supply chain.

Genus now goes beyond simply picking the best animals. It uses genomic selection, semen sexing and gene editing. Its PRRS-resistant pig (PRP) is edited to resist porcine reproductive and respiratory syndrome, one of the most costly diseases in pig farming. The US Food and Drug Administration approved it on 29 April 2025, and regulators in Latin America and Canada have followed.

In short, Genus makes money by owning elite breeding stock, improving it every generation and charging customers for access. That model has just delivered a record year.

How the business makes money

Genus PIC is the main profit engine, and much of its income comes from royalties rather than one-off sales. PIC places breeding animals and semen with producers under Royalty contracts and is paid on the pigs those customers produce. In the year to 30 June 2026, royalty Revenue was £179m, over half of PIC's £355.8m revenue. That income is recurring and linked to customers' herds.

Genus ABS runs a more traditional model, selling semen, embryos and services to cattle farmers. It is growing in sexed genetics, which lets dairy farmers choose female calves, and in beef-on-dairy breeding. It also licenses its sexing technology, for example through the IntelliGen arrangement for small dairy farmers.

The group sells into more than 85 countries. Its advantages are its proprietary herds, its intellectual property and a biosecure supply chain that rivals would struggle to copy.

Recent performance

The preliminary results for the year to 30 June 2026, published on 10 September, showed lower revenue but much higher profits. Revenue fell 2% to £658.1m, partly because PIC China was deconsolidated part-way through the year. Adjusted operating profit still rose 17% to £94.8m, adjusted pre-tax profit rose 35% to £100.2m, and adjusted Earnings Per Share rose from 81.8p to 110.3p.

Statutory pre-tax profit of £310.5m was boosted by a £204.1m gain on the China deal. Net Debt fell from £228.2m to £71.8m, which is 0.4 times EBITDA. Free Cash Flow rose 52% to £62.0m, and the total Dividend rose 10% to 35.2p.

PIC's adjusted operating profit including joint ventures rose 17% to £130.8m, and total volumes including joint ventures were up 12%. Royalties grew fastest in the China JV (up 52% on an ownership-share basis) and in Asia outside China (up 10%). North America managed just 1% after disease problems at customers in the second half. ABS revenue fell 3% to £299.8m, but its adjusted operating profit excluding JVs rose 18% to £22.6m, lifting the Margin to 7.5%. Beef volumes grew 9%. Asian revenue fell by 42% after China's restrictions on US bovine genetics effectively closed that market.

Strategy and catalysts

Three themes dominate. The first is the PRP rollout. Approvals or positive determinations are also in place in Brazil, Colombia, Argentina, the Dominican Republic, Canada, Uruguay and Peru, and commercialisation is starting in selected Latin American countries. North America is the bigger prize. Its rollout depends on approvals in Mexico and Japan, because US producers rely on those export markets. Spending on PRP rose 15% to £11.6m in FY26.

The second is China. On 31 January 2026 Genus sold 51% of PIC China to Beijing Capital Agribusiness for £123.1m and kept 49%. It received net cash of £97.7m plus a £5.6m milestone payment. Management argues that local ownership should speed up growth and commit its partner to PRP.

The third is ABS self-help. The third phase of the Value Acceleration Programme delivered a £7m in-year benefit, at an £8.2m exceptional cost. The medium-term target remains a double-digit margin.

A £60m share buyback is due to complete during FY27. For FY27, management expects adjusted pre-tax profit, at constant currency, to be in line with consensus and moderately above the normalised FY26 figure of £90.3m. The company-compiled consensus range was £87.0m to £96.6m, and profits are expected to be weighted to the second half.

Valuation talking points

The shares stood at about 2,136p on 23 September 2026. That is roughly 19 times FY26 adjusted earnings and gives a Yield of about 1.6%. This is a premium rating for an agricultural supplier, reflecting PIC's royalty income and the option value of PRP. Return on adjusted invested capital rose to 18.4% from 15.0%. Reported FY26 profit included one-offs, however. Measured against management's normalised pre-tax base of £90.3m, the multiple is higher than the headline figure suggests.

The bull case

  • PIC's royalties give recurring, herd-linked income with high margins and customers who rarely switch.
  • If Mexico and Japan approve PRP, Genus would own a distinctive disease-resistance trait with global reach.
  • The China JV turns a complex operation into a cash-rich minority stake while keeping exposure to fast royalty growth.
  • A stronger Balance Sheet funds Buybacks and dividend growth alongside R&D.
  • ABS margins are improving, which suggests the restructuring is working.

The bear case

  • The timing of PRP's US launch depends on regulators in export markets, not on Genus.
  • Disease problems in North America, low Brazilian pork prices and weak dairy prices are expected to hold back the first half of FY27.
  • China has already closed its market to US bovine genetics, and wider trade tensions could spread.
  • ABS remains lower-margin and slower-growing, and its conventional dairy volumes are falling.
  • Once one-offs are stripped out, the valuation leaves limited room for disappointment.

The bottom line

Genus (LSE:GNS) sells steady, compounding genetic improvement that farmers pay for year after year. In FY26 the model worked. Profits rose, debt fell and capital returns increased, all while PIC China was deconsolidated and ABS was restructured.

The debate now centres on PRP. Approvals in the key export markets could give Genus a trait with global reach. Delays would leave investors with a solid breeding business at a premium price. Regulatory news from Mexico and Japan is the milestone to watch.